Status:
TERMINATED
Alfuzosin Versus Placebo in Acute Urinary Retention
Lead Sponsor:
Sanofi
Conditions:
Urinary Retention
Eligibility:
MALE
50+ years
Phase:
PHASE3
Brief Summary
The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute ur...
Eligibility Criteria
Inclusion
- Men with acute urinary retention and catheterized
- Benign hypertrophia of prostate
- Patient is diagnosed in Emergency room or at a acute hospitalization
Exclusion
- Known prostate cancer
- Prior urinary retention within 30 days
- Urinary retention occurring in relation to surgery
- Blood in urine
- Difficult or impossible catheterization
- Fever \> 38 degree Celsius
- Decreased kidney function
- Permanent catheter \> 14 days
- Treatment with alfa 1 blocker within 30 days
- Meeting contraindications to treatment with Alfuzosin
- Treatment with other drugs for urinary problems
- The above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00453908
Start Date
May 1 2004
Last Update
August 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Hoersholm, Denmark